Acute Myocardial Infarction Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Acute Myocardial Infarction Market Set To Climb From $1.65 Billion In 2026 To $2.06 Billion By 2030
The acute myocardial infarction market has experienced robust expansion over recent years. Forecasts indicate it will increase from $1.56 billion in 2025 to $1.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The growth observed in the historic period is attributable to several factors, including the rising prevalence of coronary artery disease, the increasing number of hospital and specialty cardiac centers, the broader adoption of electrocardiogram and imaging techniques, heightened awareness of acute myocardial infarction symptoms, and the expansion of cardiac research initiatives.
The acute myocardial infarction market size is set to experience significant expansion over the next few years. It is projected to reach $2.06 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period stems from factors such as the development of novel thrombolytic agents, the increasing application of minimally invasive procedures, the adoption of advanced imaging technologies, the progression of personalized cardiology treatments, and the integration of AI and big data in cardiac care. Noteworthy trends for this period include the rising adoption of percutaneous coronary intervention (PCI) procedures, an increase in the use of advanced cardiac biomarkers for early diagnosis, a growing emphasis on minimally invasive cardiac treatments, the expansion of telecardiology and remote patient monitoring, and enhanced awareness and prevention programs for acute MI.
Get A Free Sample Report With In-Depth Market Insights:
Acute Myocardial Infarction Market Growth Factors Behind Sustained Expansion
The increasing number of hypertension cases is anticipated to drive the expansion of the acute myocardial infarction market in the future. Hypertension is a medical condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other health complications. The prevalence of hypertension cases is escalating due to the rising adoption of inactive lifestyles, brought on by factors such as desk jobs, extended screen time, and insufficient physical activity. Hypertension contributes to acute myocardial infarction by damaging arteries, encouraging plaque buildup, and elevating the risk of blood clots that can obstruct coronary arteries. For instance, in September 2025, the World Health Organization, a Switzerland-based intergovernmental organization, indicated that in 2024, an estimated 1.4 billion adults aged 30–79 worldwide were living with hypertension, representing about one-third of the population in this age group. Therefore, the growing incidence of hypertension is propelling the growth of the acute myocardial infarction market.
Acute Myocardial Infarction Market Segment Trends And Revenue Contributors
The acute myocardial infarction market covered in this report is segmented –
1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)
2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications
3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan
4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route
5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes
Subsegments:
1) By ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
2) By Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
Acute Myocardial Infarction Market Industry Trends Fueling Future Revenue Growth
Major companies operating in the acute myocardial infarction market are concentrating on securing regulatory approvals to expand their product portfolio, enhance treatment efficacy, and strengthen their market position. These regulatory approvals signify official authorizations from health agencies such as the FDA and EMA, confirming that drugs and medical devices meet safety, efficacy, and quality standards before being introduced to the market. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001. This drug is the world’s first developed for the emergency treatment of acute myocardial infarction (AMI). This designation acknowledges SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic areas. With promising preclinical results indicating benefits in recovery and reduced mortality, the Fast Track status enables expedited FDA communication, accelerating the approval process and ensuring quicker patient access to this innovative AMI therapy.
Acute Myocardial Infarction Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc
View The Full Acute Myocardial Infarction Market Report:
Acute Myocardial Infarction Market Top Region By Revenue And Market Share
North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
